ArticleJournal of virology2001
Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1.
Article in Journal of virology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 172 citations in OpenAlex.
- Plant Viral Vectors for Vaccine Development.Vaccines · 2026Review
- Development of a Platform for Noncovalent Coupling of Full Antigens to Tobacco Etch Virus-Like Particles by Means of Coiled-Coil Oligomerization Motifs.Molecules (Basel, Switzerland) · 2021Article
- Review
- Advancements in protein nanoparticle vaccine platforms to combat infectious disease.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2021Review
- The pharmacology of plant virus nanoparticles.Virology · 2021Review
- Plant virus particles with various shapes as potential adjuvants.Scientific reports · 2020Article
- Plant Molecular Farming as a Strategy Against COVID-19 - The Italian Perspective.Frontiers in plant science · 2020Article
- Small, Smaller, Nano: New Applications for Potato Virus X in Nanotechnology.Frontiers in plant science · 2019Review
- Production and Immunogenicity of Soluble Plant-Produced HIV-1 Subtype C Envelope gp140 Immunogens.Frontiers in plant science · 2019Article
- Recombinant helical plant virus-based nanoparticles for vaccination and immunotherapy.Virus genes · 2018Review
- Evaluating Human Immune Responses for Vaccine Development in a Novel Human Spleen Cell-Engrafted NOD-SCID-IL2rγNull Mouse Model.Frontiers in immunology · 2018Article
- A Perspective on the Development of Plant-Made Vaccines in the Fight against Ebola Virus.Frontiers in immunology · 2017Review
- Virus-based nanoparticles as platform technologies for modern vaccines.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2016Review
- An immunogen containing four tandem 10E8 epitope repeats with exposed key residues induces antibodies that neutralize HIV-1 and activates an ADCC reporter gene.Emerging microbes & infections · 2016Article
- Different applications of virus-like particles in biology and medicine: Vaccination and delivery systems.Biopolymers · 2016Review
- Modulating immunogenic properties of HIV-1 gp41 membrane-proximal external region by destabilizing six-helix bundle structure.Virology · 2016Article
- Article
- Immunogenic properties of a trimeric gp41-based immunogen containing an exposed membrane-proximal external region.Virology · 2015Article
- When plant virology met Agrobacterium: the rise of the deconstructed clones.Plant biotechnology journal · 2015Review
- Plant Viruses as Nanoparticle-Based Vaccines and Adjuvants.Vaccines · 2015Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The high-yield expression of a neutralizing epitope from human immunodeficiency virus type 1 (HIV-1) on the surface of a plant virus and its immunogenicity are presented. The highly conserved ELDKWA epitope from glycoprotein (gp) 41 was expressed as an N-terminal translational fusion with the potato virus X (PVX) coat protein. The resulting chimeric virus particles (CVPs), purified and used to immunize mice intraperitoneally or intranasally, were able to elicit high levels of HIV-1-specific immunoglobulin G (IgG) and IgA antibodies. Furthermore, the human immune response to CVPs was studied with severe combined immunodeficient mice reconstituted with human peripheral blood lymphocytes (hu-PBL-SCID). hu-PBL-SCID mice immunized with CVP-pulsed autologous dendritic cells were able to mount a specific human primary antibody response against the gp41-derived epitope. Notably, sera from both normal and hu-PBL-SCID mice showed an anti-HIV-1-neutralizing activity. Thus, PVX-based CVPs carrying neutralizing epitopes can offer novel perspectives for the development of effective vaccines against HIV and, more generally, for the design of new vaccination strategies in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.